ACE and metabolic syndrome: Considering cardiovascular risk factors, 83% of patients were hypertensive and were treated with beta-blockers (48%), angiotensin-converting enzyme (ACE) inhibitors (42%) or angiotensin receptor blockers (ARBs) (27%); 51% of patients had dyslipidemia, and 38% had diabetes; 20% of patients were smokers.